Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Division of Clinical Neurology

Head

Kevin Talbot

Head of Clinical Neurology and Professor of Motor Neuron Biology

kevin.talbot@ndcn.ox.ac.uk

01865 223380

People

Who is based in this Division?

Find out more

Contact

t: 01865 234829 e: enquiries@ndcn.ox.ac.uk

How to find us

What do we do?

MRC Brain Network Dynamics Unit Diseases of the central nervous system include many of the most disabling conditions, such as multiple sclerosis (MS), stroke, motor neuron disease (MND), Alzheimer’s disease and Parkinson’s disease. These disorders have great cost to patients, their family and carers, and to society as a whole.

We want to understand underlying disease mechanisms in order to treat these conditions effectively.

We are based in the West Wing of the John Radcliffe Hospital. This provides the perfect setting to share facilities, expertise and knowledge, as well as realise our goal of applying our learning in clinical practice.

Read the history of the Division of Clinical Neurology.

What's new

The role of artificial intelligence in spotting the onset of Parkinson’s disease

29 November 2018
World’s largest autism grant will transform research landscape

26 October 2018
Prestigious Zülch Prize for Angela Vincent

17 September 2018

MRC Brain Network Dynamics Unit

Find out more

Academic Neuropathology Unit

Find out more

Research Groups

Research, diagnostic and testing service of autoantibodies associated with neurological diseases.

Autoimmune Neurology Group

We want to understand how - and why - brain function can be disturbed to lead to inattention, poor memory and abnormal decision making. Our aim is to develop new treatments for these conditions across a range of neurological disorders.

Cognitive Neurology Research Group

We provide a nationally commissioned specialised service for the diagnosis and management of children and adults in whom a congenital myasthenic syndrome is suspected.

Congenital Myasthenia Service

Neuromyelitis optica (NMO) is a rare disease causing inflammation in the spinal cord and optic nerves. The NMO service brings together expertise in diagnostics and clinical management to improve outcomes for this often isolated group of patients.

Diagnostic and Advisory Service for Neuromyelitis Optica

Our goal is to define how activity in large populations of neurons is coordinated in healthy movement and how such coordination may go awry in diseases, translating this information in to improved treatment for Parkinson’s Disease and other disorders of movement.

Experimental Neurology

Our research aims to understand the characteristics of individual brain tumours, combining cutting edge brain imaging, molecular neuropathology and neurosurgical techniques to develop personalized approaches for first-line cancer surgery.

Glioma Neurosurgery Research Group

CPSD runs several research studies looking into the causes, investigation, and management of large artery atherosclerosis, carotid stenosis, vertebral artery disease and intracranial atherosclerosis.

Large Artery Disease

Memory Research Group

Memory Research Group

Our group uses computer simulations and mathematical analyses to understand the information processing and activity dynamics of brain networks underlying decision making. We use these models to investigate how neural circuits work in the healthy state, how their dynamics deteriorate in neurological disorders, and how their dynamics and information processing may be best restored by treatments.

Models of Brain Decision Networks

Our aim is to understand fundamental biological processes that could inform the development of targeted therapies and innovative biomarkers in neurodegenerative and neurogenetic disorders.

Molecular Neurodegeneration Research Group

Our group aims to deliver the highest quality translational and clinical research within both investigator- and commercial-led clinical trials with a focus on relieving the disease burden of MS to patients and their carers.

Multiple Sclerosis Clinical Trials Unit

Our aim is to gain a better understanding of the response of the peripheral nervous system to injury in order to develop strategies to promote peripheral nerve repair and to prevent the development of neuropathic pain. To do this we employ a variety of multi-disciplinary techniques ranging from transgenic models to human psychophysical studies and genetics.

Neural Injury Group

This cross-disciplinary research group links neuropathology, endocrinology and molecular genetics to explore how the genetics and epigenetics of pituitary tumours influences clinical characteristics and to identify targets for therapeutic intervention.

Neuro-Endocrinology Research Group

Our projects study cognitive/psychiatric disorders and comparative evolutionary neuroscience. We are interested in the relationship between brain structure and function in disease, development and aging - particularly related to language and social cognition.

Neuroanatomy and Cognition Group

We explore the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases using a multidisciplinary team approach to post-mortem brain and spinal cord tissue. The aim is that the understanding derived from these studies will translate into ideas for improved treatments for living patients.

Neurodegeneration and Inflammation Research Group

Our objective is to develop ways of accurately measuring neurological disorders such as Parkinson's disease.

NeuroMetrology Lab

We work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.

Neuromuscular Disorders

The Oxford Project to Investigate Memory and Ageing (OPTIMA) started in 1988 and the last LEAD participants were seen in March 2015. We are no longer recruiting to any of the cohorts. However, we are currently creating the OPTIMA Legacy Resource from which data collected from the OPTIMA cohorts is available and samples are biobanked and available. Brain tissue is available as part of the Brains For Dementia Research (BDR) collection.

OPTIMA

We are a forward-looking dynamic group interested in all aspects of clinical and experimental epileptology with an emphasis on clinically relevant research. The Group draws together all relevant disciplines across Oxford University Hospitals and the University of Oxford.

Oxford Epilepsy Research Group

Oxford Motor Neuron Disease Centre

Oxford Motor Neuron Disease Centre

The Oxford Vascular Study (OxVasc) investigates vascular diseases (e.g. strokes, heart attacks) in patients registered with eight general practices in Oxfordshire. We run a rapid-access clinic for patients with suspected Transient Ischaemic Attacks (TIAs) or minor strokes.

Oxford Vascular Study

We study why certain neuronal populations are vulnerable to neurodegeneration in Parkinson’s disease brain and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.

Parkinson’s Neuropathology Group